Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Jun 2;211(6):1049–1062. doi: 10.1084/jem.20131751

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 Ahn et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

PMC Copyright notice

Figure 3. — RU-505 prevented altered thrombosis and fibrinolysis in AD transgenic mice. (A) After craniotomy, three concentrations of FeCl₃ (5, 10, and 15%) were incrementally administered to the surface of the brains of vehicle- or RU-505–treated WT and Tg6799 mice (Videos 1–4), and clotting of cerebral blood vessels (>20 µM) was imaged (bars, 200 µm). Representative intravital images shows the surface of the brains of vehicle- or RU-505–treated WT and Tg6799 mice before FeCl₃ treatments or 5 min after 15% FeCl₃ treatments. (B and C) Frequency of clotted vessels was calculated at increasing concentrations of FeCl₃ (B) and was plotted for 15% FeCl₃ treatment (C; ***, P < 0.001; n = 5 mice per group). All values are means and SEM. Results are from two independent experiments.